We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
A new world is possible. Let's not go back to what wasn't working anyway.
Add this topic to your myFT Digest for news straight to your inbox
VietJet founder Nguyen Thi Phuong Thao’s $211m gift to Linacre draws criticism
Louise Richardson says ‘informality’ and ‘flexibility’ are key in leading an ancient university with its disputatious devolved colleges
Key members of Oxford’s scientific team reveal the exhaustive effort and care that went into the race to create a ‘vaccine for the world’
Peter Lampl put his financial muscle into boosting educational access for all — but the pandemic has made progress harder than ever
Sculptor says move would help to address ‘collective amnesia’ over memorials
Sasha Johnson supporters hit out after London force says ‘nothing to suggest’ attack was targeted
Student group finds 1,000 workers were paid below city’s living wage of £10.31 an hour
We at the university, alongside the drugmaker, felt we should not profiteer from a pandemic
Property investors pile into life sciences sector as part of shift away from retail and offices
Declining infection rates mean potential risks from jab may outweigh dangers of disease
Jab developed by University of Oxford team proves 77% effective in Burkina Faso mid-stage tests
Some on vaccine committee take cautious line over blood clots, while others fear impact on inoculation rollout
Brussels puts focus on mRNA vaccines amid concern over rare blood clots linked to other shots
Decision to restrict jab only for people under 30 contrasts with tougher stance in other countries
Clinical testing of jab with small group aged 6-17 suspended ahead of risk review from regulators
Hamilton Lane denies targeting professor who published study that rocked industry
Intranasal vaccines would be easier to administer and could cut transmission rates
History provides a window into how the coronavirus outbreak might come to a close
New vaccine producers and mRNA technology are shaking up the market
Emmanuel Macron forced to extol its virtues after efficacy doubts and adverse publicity damped trust
UK prime minister insists jab effective in preventing death and serious illness from new variants
E484K, the genetic change in the variant first identified in South Africa, is affecting the efficacy of some vaccines
Chancellor sees active role for the state in future in nurturing innovation
Scientists say research supports UK plan to delay second dose of Covid-19 vaccine
New Oxford analysis, not yet peer-reviewed, shows single jab to be 76% effective for up to 12 weeks
International Edition
